PO.PR02.02 · 预防研究

PanGIA分析系统:一种通过尿液对多种癌症进行无创诊断的新型机器学习平台

PanGIA Analysis System, a novel machine learning platform for non-invasive diagnosis of multiple cancers through urine

编号 7620 展板 7 时间 4/22 09:00–12:00 区域 Section 36 主讲 OBDULIO PILOTO, PhD
分会场 Cancer and Cancer Related Alterations, Detection Approaches, and Molecular Characterization
该海报暂无可下载的资料 AACR 官方页面

作者与单位 Authors & Affiliations

Abhignyan Nagesetti, Francis Lim, Nick Gonzalez, Miguel Javiel, Pablo Hernandez, Kyle Ambert, Robert Cardwell, Obdulio Piloto

PanGIA Biotech Inc., Miami, FL

摘要 Abstract

中文摘要
PanGIA分析系统(PAS)代表了一种新型的、由机器学习驱动的平台,可通过生化特征图谱分析来解析复杂的生物系统。与Google Gemini或ChatGPT等先进语言模型类似,PAS采用经过训练的算法来解读源自生物样本的多维数据。该系统利用称为NuTec Slides的专有水凝胶微阵列基质,旨在从多种液体基质中无偏倚地捕获生物分子图谱。其中,尿液是一种信息尤为丰富但尚未充分利用的介质,可用于评估生理和病理状态。在本研究中,评估了一款可商业化的PAS原型区分含有癌症相关分析物的尿液样本与未加标对照样本的能力。将健康志愿者的晨起首次尿液混合,并加入文献验证的、代表血液系统癌症以及乳腺癌、骨癌和脑癌的分析物组合。将NuTec Slides与加标和未加标样本孵育后,进行基于热的信号显影和扫描,提取的图像特征数据通过主成分分析(PCA)进行分析。这项概念验证研究表明,PAS能够区分含有文献支持分析物的加标人类尿液样本与对照样本。此外,我们观察到各类癌症之间存在明显的聚类。结论:这些发现证明了PAS作为一种基于尿液生物分子图谱分析的无创癌症检测工具的可行性。有必要继续开展临床验证,以确立其在诊断、预后、伴随诊断和微小残留病监测方面的更广泛应用价值。
查看英文原文 English abstract
The PanGIA Analysis System (PAS) represents a novel machine learning-driven platform for the interrogation of complex biological systems through biochemical signature profiling. Analogous to advanced language models such as Google Gemini or ChatGPT, PAS employs trained algorithms to interpret multidimensional data derived from biological samples. The system utilizes proprietary hydrogel-based microarray substrates, termed NuTec Slides, designed to capture unbiased biomolecular profiles from diverse liquid matrices. Among these, urine offers a particularly informative yet underutilized medium for assessing physiological and pathological states. In this study, a commercialization-ready prototype of PAS was evaluated for its ability to discriminate urine samples containing cancer-associated analytes from non-spiked controls. First-morning urine from healthy volunteers was pooled and spiked with literature-validated analyte panels representing hematological cancers, breast, bone, and brain cancers. Following incubation of NuTec Slides with both spiked and unspiked samples, heat-based signal development, and scanning, extracted image feature data were analyzed by principal component analysis (PCA). This proof-of-concept study indicates that PAS can distinguish between control and spiked human urine samples containing literature supported analytes. Furthermore, we observe distinct clustering between individual cancers. Conclusion: These findings demonstrate the feasibility of PAS as a non-invasive diagnostic tool for cancer detection using urine-based biomolecular profiling. Continued clinical validation is warranted to establish its broader utility in diagnostics, prognostics, companion diagnostics, and monitoring of minimal residual disease.
利益披露 Disclosure
A. Nagesetti, PanGIA Biotech Inc. Employment. F. Lim, PanGIA Biotech Inc. Employment. N. Gonzalez, PanGIA Biotech Inc. Employment. M. Javiel, PanGIA Biotech Inc. Employment. P. Hernandez, PanGIA Biotech Inc. Employment. K. Ambert, PanGIA Biotech Inc. Employment. R. Cardwell, PanGIA Biotech Inc. Employment, g., Board of Directors, non-salaried role), Stock. O. Piloto, PanGIA Biotech Inc. Employment, g., Board of Directors, non-salaried role), Stock.

← 返回 AACR 2026 检索